|Salary:||£30,655 to £38,428 per annum plus excellent benefits.|
|Contract Type:||Contract / Temporary|
|Placed on:||29th September 2016|
|Closes:||26th October 2016|
|★ View Employer Profile|
Fixed-term for 3 years
A postdoctoral position is available at the Wellcome Trust Sanger Institute (WTSI) under the leadership of Dr Daniel Gaffney (WTSI), Dr David Tough and Dr Matthew Edwards (both at GlaxoSmithKline, Stevenage). The positions provide an exciting opportunity for the successful candidates to apply cutting edge technology, utilizing induced pluripotent stem cells (IPSC) and CRISPR/Cas genome editing, to identify new potential therapeutic targets for immune-mediated diseases. The project builds on recent initiatives at the Sanger Institute to generate large numbers of human IPS cells (HIPSCI: http://www.hipsci.org. The positions are part of a new translational initiative at the Wellcome Trust Genome Campus, OpenTargets (https://www.opentargets.org).
The goal of the project is to dissect the genetic architecture of immune cell phenotypes using an IPSC-based screening platform. Specifically, the post-holders will be responsible for developing and optimizing a protocol for the generation of IPSC-derived dendritic cells, characterizing these cells at phenotypic, functional and molecular levels, developing and executing CRISPR - Cas based screens in these cells to identify immune-modulatory targets, and validating putative targets in IPSC-derived and primary dendritic cells. We welcome candidates with a background in cell biology, molecular biology and/or immunology with extensive experience in performing cell and molecular biological assays. Experience in mammalian cell culture and flow cytometry are highly desirable, as is a background with handling human immune cells. The candidates will have the opportunity to interact with active computational and experimental research teams working at the Wellcome Trust Sanger Institute , and at GlaxoSmithKline (GSK), using cutting edge genomic and cellular techniques.
Open Targets is a recently established pioneering public-private initiative between GSK, EMBL-EBI (European Bioinformatics Institute) and the WTSI, located on the Wellcome Trust Genome Campus in Hinxton, near Cambridge, UK. Open Targets aims to generate evidence on the biological validity of therapeutic targets and provide an initial assessment of the likely effectiveness of pharmacological intervention on these targets, using genome-scale experiments and analysis. Open Targets aims to provide an R&D framework that applies to all aspects of human disease, and to share its data openly with the scientific community. The goal of the platform is to harness the power of 'big data' and genome sequencing to improve the success rate for discovering new medicines and share its data openly in the interests of accelerating drug discovery.
Closing date for applications: 26th October 2016, however applications will be considered and reviewed on an on-going basis and therefore the post may be filled before the deadline.